

Table of contents

EXECUTIVE SUMMARY.....	5	5. VALUATION OF COMPANIES OF THE INDUSTRY...	98
INTRODUCTION.....	7	5.1 Valuation methodology.....	99
1. GENERAL INFORMATION.....	8	5.2 Valuation of the manufacturing companies of the sector (2012-2014)	100
1.1 Industry definition.....	9	5.3 Valuation of the importing companies of the sector (2012-2014)	101
1.2 Industry general facts & figures.....	10	6.MARKET.....	102
1.3 Drug distribution channel.....	11	6.1 Total domestic market size of pharmaceutical companies (2009-2014)	103
1.4 Industry characteristics.....	12	6.2 Domestic market size of manufacturing pharmaceutical companies (2009-2014)	104
2. INSTITUTIONAL FRAMEWORK.....	13	6.3 Domestic market size of importing pharmaceutical companies (2009-2014)	105
2.1 Institutional framework.....	14	6.4 Drug sales.....	106
2.2 Pricing.....	25	6.5 Pharmaceuticals domestic production	108
2.3 Prescription.....	40	6.6 Gross added value of pharmaceutical production.....	109
3. DEMAND.....	43	6.7 External trade of drugs.....	110
3.1 Determinants of demand.....	44	6.8 Generic medicines domestic market size(2011-2014)	111
3.2 Analysis of selected determinants of demand	47	6.9 Medicine main segmentation.....	112
4. SUPPLY.....	64	6.10 Porter's five forces.....	113
4.1 Turnover index for basic pharmaceutical products.....	66		
4.2 Leading manufacturing companies.....	67		
4.3 Leading importing companies.....	69		
4.4 Financial analysis of the industry (2009-2014)	72		
4.5 Comparative financial assessment of major manufacturing companies (2014)	90		
4.6 Comparative financial assessment of major importing companies (2014)	94		

Table of contents

7. INTERNATIONAL MARKET.....	117	C. Activity indicators.....	228
7.1 International market.....	118	D. Performance indicators.....	252
7.2 European market.....	122	Financial formulas.....	272
7.3 Research and development in the European pharmaceutical market.....	130	SOURCES & BIBLIOGRAPHY.....	273
7.4 Innovation performance in EU-28.....	131		
8. CONCLUTIONS-PROSPECTS.....	132		
8.1 SWOT analysis.....	133		
8.2 Main findings- Prospects.....	134		
APPENDIX I.....			
Financial indicators of major manufacturing pharmaceutical companies (2009-2014).....	137		
A. Capital structure and financial leverage indicators.....	138		
B. Liquidity indicators.....	153		
C. Activity indicators.....	162		
D. Performance.....	180		
APPENDIX II.....			
Financial indicators of major importing pharmaceutical companies (2009-2014).....	195		
A. Capital structure and financial leverage indicators.....	196		
B. Liquidity indicators.....	216		